MELAS SyndromeNCT02114554
Mitochondrial nt3243 A>G Mutation in Taiwan
An observational study of MELAS Syndrome and Noninsulin-dependent Diabetes Mellitus With Deafness, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Mitochondrial diseases are multisystem disorders that present with a wide range of clinical manifestations. Mitochondrial DNA nt3243A>G mutation is one of the most common mutations seen in mitochondrial diseases. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- MELAS Syndrome, Noninsulin-dependent Diabetes Mellitus With Deafness
- How many people
- 40 participants
- Where
- 1 siteTaiwan
- Study dates
- Jan 2014to Jan 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with mitochondrial DNA nt3243 A>G mutation detected at National Taiwan University Hospital.
Who may be able to join
- -Patients with mitochondrial DNA nt3243 A>G mutation
Who cannot join
- -Patients without confirmed mitochondrial DNA nt3243 A>G mutation
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei, 100
Han-Chung Hsiue, MD, 886-23123456 ext. 66064, hanchunghsiue@gmail.com
Pei-Lin Lee, MD, PhD
About this study
Official title: Clinical Characteristics and Prognostic Factors of Mitochondrial nt3243 A>G Mutation in Taiwan
Mitochondrial diseases are multisystem disorders that present with a wide range of clinical manifestations. Mitochondrial DNA nt3243A>G mutation is one of the most common mutations seen in mitochondrial diseases. Syndromes associated with this mutation include mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD), myoclonic epilepsy with ragged red fibers (MERRF), and chronic progressive external ophthalmoplegia (CPEO). Clinical analyses of mitochondrial DNA nt3243A>G mutation from Taiwan remain scarce. The present study aims to investigate the clinical features and prognostic factors of patients with mt3243A>G mutation in Taiwan.
Read the detailed description
Patients and clinical features. The study will be carried out at National Taiwan University hospital, a tertiary medical center in Taipei. The Medical Genetics Department at National Taiwan University Hospital receives referral and conducts genetic testing for hospitals all around Taiwan. We will review the medical chart of all patients with documented mitochondrial DNA nt3243 point mutation. Demographic data, age at onset of symptoms, clinical features (including stroke, seizure-like episode, lactic level, diabetes mellitus, hearing impairment, myopathy, electrocardiogram abnormality, chronic progressive external ophthalmoplegia), relevant family history, treatment, and outcome will be recorded. Full MELAS phenotype was defined as the presence of focal central nervous system events, either seizures, strokes, or both.
Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA purification kit (Gentra Systems, Minneapolis, Minnesota, USA). Polymerase chain reaction (PCR) for mitochondrial DNA nt3243 point mutation was carried out by left primer 5'-cggagtaatccaggtcggtt-3' and right primer 5'-ggaattgaacctctgactgt-3'. Presence of mitochondrial DNA nt3243 A>G mutation was detected after Hae III restriction enzyme digestion.
Heteroplasmy of mitochondrial nt3243A>G mutation was detected by real-time amplification refractory mutation system quantitative PCR (ARMS-qPCR) assay as previously reported [19]. In brief, wild-type and mutant-target primers, each 500 nM, were added into a 10-ml PCR reaction containing 1X KAPA SYBR® FAST ABI Prism® qPCR Master Mix (KAPABIOSYSTEMS, Cat No. KK4603) and 4 ng of genomic DNA. Real-time PCR conditions were 2 min at 50°C, 20 seconds at 95°C, followed by 40 cycles of 15 seconds of denaturation at 95°C and 30 seconds of annealing/extension at 62°C. Data of cross point and concentration fluorescent signal intensity of PCR products was recorded and analyzed by ABI StepOnePlusTM Real-Time PCR System (Applied Biosystems) and StepOne software v2.1 (Applied Biosystems). The threshold cycle ( CT value) within the linear exponential phase was used to construct the standard curve and to measure the original copy number of DNA template. The percentage of the mutant mtDNA was calculated using formula as below: Heteroplasmy %= 1/(1+ 1/2△CT).
Statistical analysis. SPSS 17.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Results were given as median and range, or mean ± 1 SD, when appropriate. Student 's t-test was used to compare unpaired groups. Fisher's exact test was used to determine associations between two categorical variables. Cox-regression model was used to analyze possible prognostic factors. Inter-group differences at outcome were compared by Kaplan-Meier estimate and log-rank test. Pearson's correlation was used to correlate heteroplasmy to age of diagnosis. A p value < 0.05 was considered statistically significant.
- Keywords
- MELAS, MIDD, Heteroplasmy
- Medical subject headings
- MELAS Syndrome, Noninsulin-dependent diabetes mellitus with deafness
What is being measured
The primary outcome is the main question the study is designed to answer.
Prognostic factors for poor outcome
Poor outcome includes death and development of poor performance (a modified Rankin scale 4 or higher). Univariate and multivariate analyses will be utilized to study whether specific clinical presentations (for instance, the presence of stroke, seizure, diabetes, etc.) and degree of heteroplasmy are associated with poor outcome.
Measured: Within follow-up period, which is estimated to be 5 years in average.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2014 (estimated)
- Study startJan 2014
- Primary completionJan 2015 (estimated)
- Study completionJan 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MELAS SyndromeStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Cheng-Kung University Hospital
- Responsible party
- Sponsor
- Investigators
- Pei-Lin Lee, MD, PhD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02114554
- Sponsor's protocol ID
- 201307058RINB
- Status last verified
- Apr 2014
- First submitted
- 9 Feb 2014
- Last updated
- 15 Apr 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics and Prognostic Factors of Mitochondrial nt3243 A>G Mutation in Taiwan
- ClinicalTrials.gov ID
- NCT02114554
- Acronym / sponsor ID
- 201307058RINB
- Keywords
- MELAS, MIDD, Heteroplasmy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Collaborators
- National Cheng-Kung University Hospital
- Study start
- Jan 2014
- Primary completion
- Jan 2015 (estimated)
- Study completion
- Jan 2015 (estimated)
- First posted
- 15 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mitochondrial diseases are multisystem disorders that present with a wide range of clinical manifestations. Mitochondrial DNA nt3243A>G mutation is one of the most common mutations seen in mitochondrial diseases. Syndromes associated with this mutation include mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD), myoclonic epilepsy with ragged red fibers (MERRF), and chronic progressive external ophthalmoplegia (CPEO). Clinical analyses of mitochondrial DNA nt3243A>G mutation from Taiwan remain scarce. The present study aims to investigate the clinical features and prognostic factors of patients with mt3243A>G mutation in Taiwan.
Detailed description
Patients and clinical features. The study will be carried out at National Taiwan University hospital, a tertiary medical center in Taipei. The Medical Genetics Department at National Taiwan University Hospital receives referral and conducts genetic testing for hospitals all around Taiwan. We will review the medical chart of all patients with documented mitochondrial DNA nt3243 point mutation. Demographic data, age at onset of symptoms, clinical features (including stroke, seizure-like episode, lactic level, diabetes mellitus, hearing impairment, myopathy, electrocardiogram abnormality, chronic progressive external ophthalmoplegia), relevant family history, treatment, and outcome will be recorded. Full MELAS phenotype was defined as the presence of focal central nervous system events, either seizures, strokes, or both.
Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA purification kit (Gentra Systems, Minneapolis, Minnesota, USA). Polymerase chain reaction (PCR) for mitochondrial DNA nt3243 point mutation was carried out by left primer 5'-cggagtaatccaggtcggtt-3' and right primer 5'-ggaattgaacctctgactgt-3'. Presence of mitochondrial DNA nt3243 A>G mutation was detected after Hae III restriction enzyme digestion.
Heteroplasmy of mitochondrial nt3243A>G mutation was detected by real-time amplification refractory mutation system quantitative PCR (ARMS-qPCR) assay as previously reported [19]. In brief, wild-type and mutant-target primers, each 500 nM, were added into a 10-ml PCR reaction containing 1X KAPA SYBR® FAST ABI Prism® qPCR Master Mix (KAPABIOSYSTEMS, Cat No. KK4603) and 4 ng of genomic DNA. Real-time PCR conditions were 2 min at 50°C, 20 seconds at 95°C, followed by 40 cycles of 15 seconds of denaturation at 95°C and 30 seconds of annealing/extension at 62°C. Data of cross point and concentration fluorescent signal intensity of PCR products was recorded and analyzed by ABI StepOnePlusTM Real-Time PCR System (Applied Biosystems) and StepOne software v2.1 (Applied Biosystems). The threshold cycle ( CT value) within the linear exponential phase was used to construct the standard curve and to measure the original copy number of DNA template. The percentage of the mutant mtDNA was calculated using formula as below: Heteroplasmy %= 1/(1+ 1/2△CT).
Statistical analysis. SPSS 17.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Results were given as median and range, or mean ± 1 SD, when appropriate. Student 's t-test was used to compare unpaired groups. Fisher's exact test was used to determine associations between two categorical variables. Cox-regression model was used to analyze possible prognostic factors. Inter-group differences at outcome were compared by Kaplan-Meier estimate and log-rank test. Pearson's correlation was used to correlate heteroplasmy to age of diagnosis. A p value < 0.05 was considered statistically significant.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with mitochondrial DNA nt3243 A>G mutation detected at National Taiwan University Hospital.
Key inclusion criteria (1 listed)
- -Patients with mitochondrial DNA nt3243 A>G mutation
Key exclusion criteria (1 listed)
- -Patients without confirmed mitochondrial DNA nt3243 A>G mutation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prognostic factors for poor outcome
Time frame: Within follow-up period, which is estimated to be 5 years in average.
Poor outcome includes death and development of poor performance (a modified Rankin scale 4 or higher). Univariate and multivariate analyses will be utilized to study whether specific clinical presentations (for instance, the presence of stroke, seizure, diabetes, etc.) and degree of heteroplasmy are associated with poor outcome.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2014.
Related trials for MELAS Syndrome
RecruitingPhase 3
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD)
Not yet recruitingPhase 1/2
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
RecruitingObservational study
Global Registry and Natural History Study for Mitochondrial Disorders
Mitochondrial Diseases, Kearns-Sayre Syndrome
RecruitingObservational study
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Mitochondrial Disorders, Mitochondrial Genetic Disorders
RecruitingPhase 1
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
Mitochondrial Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pei-Lin Lee, MD, PhD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of MELAS Syndrome and Noninsulin-dependent Diabetes Mellitus With Deafness, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Han-Chung Hsiue, MD (886-23123456 ext. 66064, hanchunghsiue@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prognostic factors for poor outcome (time frame: Within follow-up period, which is estimated to be 5 years in average.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2014.